Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page + Q$ i0 ]4 n+ I4 @$ d) }$ H
* z3 P+ M f8 r6 {; F5 H# g+ `" @" Z1 w5 a+ A' W7 B# t
Sub-category:
: D9 o3 [+ |. a4 ^; UMolecular Targets
4 ~9 W* m; y6 l" ` m4 g4 E* S+ Z1 i# y" G' T
) @6 F* [6 L" n9 H
Category:% a$ n' V$ w# ?4 M
Tumor Biology
1 o; @% S6 J& P& [- e* W2 s; \# s- `0 A
& P( R- D: ^: W) x* kMeeting:
$ Q! ?; {+ f( ]/ ^& C2 {, x+ @2011 ASCO Annual Meeting ( t+ i2 a9 G: ]0 L. F, G$ d
; Z6 ^7 ?4 \; J# z3 \4 O0 U. J' C
! l; ]$ f* P) s* | F7 T& m; bSession Type and Session Title:
% e T2 J% [+ C: M/ F5 X8 WPoster Discussion Session, Tumor Biology
7 Q# p0 l4 y! ?/ V0 R1 P) S! a1 W$ |0 k- ~: T* r% g5 n
- g5 t/ _8 ~; m5 P$ sAbstract No:
' G( S& v, z% m; g* \" n10517 ' N* O# m4 d6 m( r$ o2 M% d
+ ?3 a5 b1 z* G) a+ D
1 s" ?$ `2 v: n) p/ @Citation:! c6 `4 i) }1 I Z* w* {% n
J Clin Oncol 29: 2011 (suppl; abstr 10517) 1 }2 [5 G( b0 H
3 |2 g J# F" P: w) K) n2 q' j
2 S% q4 a4 _! I1 [ E/ b2 [$ |
Author(s):( w) q1 @5 a8 O- G1 w X
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 3 I/ o8 d/ [. c+ v" ]8 I! M9 B
* l7 _ h; w/ r- r' A6 g b* u# z& H8 i! ?7 j" y# g
- N/ C. ~8 u/ ]- {9 o ~- O# f
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ i9 X) i7 u: |5 g
" V( I% n' O5 K0 _Abstract Disclosures
. j$ \5 _9 n9 l/ V
9 z5 Y' j O U {; } tAbstract:
1 y5 r2 M2 p* L0 ]
' u8 M. I( a; d$ L4 D' D& e! e( Z' \
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." M6 F8 n# g0 b$ n1 A
; ~9 C; l2 F: I2 n 0 d: H6 P7 n# M' ]8 T ~
|